<DOC>
	<DOCNO>NCT02117245</DOCNO>
	<brief_summary>The objective study assess bioavailability MGCD265 formulation follow oral administration feed condition ( Treatment-1 ) compare fasting condition ( Treatment-2 ) healthy male female volunteer .</brief_summary>
	<brief_title>Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers</brief_title>
	<detailed_description>The study objective ass bioavailability MGCD265 formulation follow oral administration feed condition ( Treatment-1 ) compare fasting condition ( Treatment-2 ) healthy male female volunteer .</detailed_description>
	<criteria>1 . Male female volunteer 2 . Volunteer age 40 65 year 3 . Females childbearing potential use stable contraceptive method least 14 day prior screen willing use acceptable birth control method 7 day prior first dose 30 day last dose study drug : 4 . Female volunteer consider non childbearing potential eligible : Amenorrhea least 1 year ; Hysterectomy ; Bilateral oophorectomy least 6 week prior first dose ; Bilateral tubal ligation least 6 month prior first dose ; Hysteroscopic sterilization . 5 . Male volunteer agree abstinent use acceptable contraception method collaboration female partner time take first dose 90 day last dose study drug : â€¢ Male volunteer also agree donate sperm time take first dose 90 day last dose . 6 . Volunteer body mass index ( BMI ) great equal 18.50 30.00 kg/m2 7 . Non ex smoker least 6 month . 8 . Availability entire study period 9 . Motivated volunteer absence intellectual problem likely limit validity consent participate study compliance protocol requirement 10 . Clinical laboratory value within laboratory 's state normal range ; must without clinical significance 11 . Have clinically significant disease capture medical history evidence clinically significant finding physical examination and/or clinical laboratory evaluation 12 . Willingness adhere protocol requirement The informed consent form must sign volunteer , prior participation study . 1 . Females pregnant lactate 2 . History significant hypersensitivity reaction substance drug 3 . History presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug 4 . Seated blood pressure high equal 140/90 mmHg screen 5 . Seated blood pressure high equal 140/90 mmHg drug administration 6 . History predisposition cardiovascular illness 7 . History predisposition thrombotic hemorrhagic event , bleed diathesis coagulopathy , gastrointestinal condition risk perforation , presence nonhealing wound , ulcer fracture 8 . Presence significant pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 9 . No major surgery within 28 day prior first dose 10 . Suicidal tendency , disposition seizure , state confusion , clinically relevant psychiatric disease 11 . Presence outofrange cardiac interval ECG abnormalities 12 . Maintenance therapy drug , history drug dependency alcohol abuse 13 . Any clinically significant illness previous 28 day day 1 study 14 . Use enzymemodifying drug previous 28 day day 1 study 15 . Use drug know induce inhibit hepatic metabolism previous 28 day day 1 study 16 . Any history tuberculosis and/or prophylaxis tuberculosis 17 . Positive urine screen ethanol and/or drug abuse 18 . Positive result HIV , HBsAg antiHepatitis C Virus test 19 . Females pregnant 20 . Volunteers take Investigational Product donate 50 mL blood previous 28 day day 1 study 21 . Donation 500 mL blood previous 56 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Food effect MGCD265 bioavailability healthy volunteer</keyword>
</DOC>